396 related articles for article (PubMed ID: 33922362)
21. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
[No Abstract] [Full Text] [Related]
22. Emerging Therapies for Advanced Cholangiocarcinoma: An Updated Literature Review.
Vignone A; Biancaniello F; Casadio M; Pesci L; Cardinale V; Ridola L; Alvaro D
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768421
[TBL] [Abstract][Full Text] [Related]
23. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies.
Marks EI; Yee NS
World J Gastrointest Oncol; 2015 Nov; 7(11):338-46. PubMed ID: 26600933
[TBL] [Abstract][Full Text] [Related]
25. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
Liu Z; Li S; Zeng J; Zhou X; Li H; Liu X; Li F; Jiang B; Zhao M; Ma T
Life Sci; 2020 Sep; 257():118068. PubMed ID: 32653521
[TBL] [Abstract][Full Text] [Related]
26. Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy.
Stakheyeva M; Riabov V; Mitrofanova I; Litviakov N; Choynzonov E; Cherdyntseva N; Kzhyshkowska J
Curr Pharm Des; 2017; 23(32):4807-4826. PubMed ID: 28714406
[TBL] [Abstract][Full Text] [Related]
27. Precision medicine in cholangiocarcinoma.
Pellino A; Loupakis F; Cadamuro M; Dadduzio V; Fassan M; Guido M; Cillo U; Indraccolo S; Fabris L
Transl Gastroenterol Hepatol; 2018; 3():40. PubMed ID: 30148225
[TBL] [Abstract][Full Text] [Related]
28. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Dong Z; Liao B; Shen W; Sui C; Yang J
Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753
[TBL] [Abstract][Full Text] [Related]
29. Latest evidence on immunotherapy for cholangiocarcinoma.
Guo X; Shen W
Oncol Lett; 2020 Dec; 20(6):381. PubMed ID: 33154779
[TBL] [Abstract][Full Text] [Related]
30. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapeutic Approaches to Biliary Cancer.
Shah UA; Nandikolla AG; Rajdev L
Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
[TBL] [Abstract][Full Text] [Related]
32. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract][Full Text] [Related]
33. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in advanced gastric cancer, is it the future?
Coutzac C; Pernot S; Chaput N; Zaanan A
Crit Rev Oncol Hematol; 2019 Jan; 133():25-32. PubMed ID: 30661655
[TBL] [Abstract][Full Text] [Related]
35. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM
Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989
[TBL] [Abstract][Full Text] [Related]
36. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
[TBL] [Abstract][Full Text] [Related]
37. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
38. Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type.
Shiao MS; Chiablaem K; Charoensawan V; Ngamphaiboon N; Jinawath N
Front Genet; 2018; 9():309. PubMed ID: 30158952
[TBL] [Abstract][Full Text] [Related]
39. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
Sabbatino F; Villani V; Yearley JH; Deshpande V; Cai L; Konstantinidis IT; Moon C; Nota S; Wang Y; Al-Sukaini A; Zhu AX; Goyal L; Ting DT; Bardeesy N; Hong TS; Fernandez-del Castillo C; Tanabe KK; Lillemoe KD; Ferrone S; Ferrone CR
Clin Cancer Res; 2016 Jan; 22(2):470-8. PubMed ID: 26373575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
